NCT Number: NCT02117544
Multifocal High ADD Contact Lens Proof of Concept Trial
The purpose of this study is to evaluate the visual performance of a new multifocal High ADD contact lens compared to the currently-marketed AIR OPTIX® AQUA MULTIFOCAL (AOAMF) High ADD Contact Lens.
Looking for future studies?
Notify MeKey information
Conditions
Age range
50 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Must sign an Informed Consent document;
- Presbyopic and require at least 2.25 diopters (D) spectacle ADD power;
- Current or previous soft contact lens wearer;
- Not able to achieve monocular near visual acuity (VA) 0.2 logarithm of the Minimum Angle of Resolution (logMAR) [Early Treatment of Diabetic Retinopathy Study (ETDRS)] or better in each eye with AIR OPTIX® AQUA Multifocal (AOAMF) High ADD Contact Lenses;
- Willing and able to wear multifocal contact lenses in both eyes within the available range of powers for this trial;
- Manifest cylinder less than or equal to 1.00 D;
- Able to achieve best corrected visual acuity (BCVA) of 20/25 or better in each eye at distance (as determined by manifest refraction);
- Other protocol-defined inclusion criteria may apply.
Exclusion criteria
- Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment, as determined by the investigator;
- Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; or any use of topical ocular medications that would require instillation during contact lens wear;
- Any history of herpetic keratitis;
- History of corneal or refractive surgery, irregular cornea or unilateral pseudophakia;
- Biomicroscopy findings (except for corneal vascularization) that are moderate (Grade 3) or severe (Grade 4);
- Corneal vascularization that is mild (Grade 2) or higher;
- A pathologically dry eye that precludes contact lens wear;
- Monocular (only 1 eye with functional vision);
- Anisometropia ≥ 1.50 D (contact lens distance prescription);
- Clinically significant (> 1 millimeter) anisocoria;
- History of intolerance or hypersensitivity to any component of the investigational products;
- Concurrent participation in a contact lens or contact lens care product clinical trial within the previous 30 days;
- Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment;
- Any ocular or systemic medical condition that may, in the opinion of the Investigator, preclude safe administration of the study lenses or affect the results of this study;
- Other protocol-defined exclusion criteria may apply.
Treatment and study plan
Lotrafilcon B multifocal contact lenses
DeviceOther names: AIR OPTIX® AQUA Multifocal, AOAMF
Primary outcomes
-
High Contrast Visual Acuity (HCVA) Near Monocular
Time frame: Day 1, 10 minutes after lens insertion, each product
Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HCVA was assessed monocularly (each eye separately) at 40 centimeters using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and measured in logarithm of the minimum angle of resolution (logMAR), with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value indicates better visual acuity. Both eyes contributed to the analysis.
Secondary outcomes
-
HCVA Distance Monocular
Time frame: Day 1, 10 minutes after lens insertion, each product
Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HCVA was assessed monocularly (each eye separately) at 6 meters using an ETDRS chart and measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value indicates better visual acuity. Both eyes contributed to the analysis.
-
HCVA Intermediate Monocular
Time frame: Day 1, 10 minutes after lens insertion, each product
Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HCVA was assessed monocularly (each eye separately) at 1 meter using an ETDRS chart and measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value indicates better visual acuity. Both eyes contributed to the analysis.
-
Low Contrast Visual Acuity (LCVA) Distance Monocular
Time frame: Day 1, 10 minutes after lens insertion, each product
Visual Acuity (clarity or sharpness of vision) was measured at low contrast level. LCVA was assessed monocularly (each eye separately) at 6 meters using an ETDRS chart and measured in logMAR, with 0.1 logMAR increment corresponding to 5 letters, or 1 line, on the ETDRS chart. A lower logMAR value indicates better visual acuity. Both eyes contributed to the analysis.
Sponsors and collaborators
Lead sponsor
Alcon Research
Industry
Registry information
Official study title
Evaluation of Visual Performance With a Multifocal High ADD Soft Contact Lens Design
Important dates
- Study start
- 2014
- Primary completion
- 2014
- Study completion
- 2014
- First posted
- Apr 21, 2014
- Registry last updated
- Aug 26, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Evaluate the Efficacy and Safety of CTO0307 in Adults With Presbyopia
NCT07723716
Eye Diseases, Presbyopia
Seoul, South Korea
View Trial DetailsSafety and Efficacy of Nyxol Eye Drops as a Single Agent and With Adjunctive Low-Dose Pilocarpine Eye Drops in Subjects With Presbyopia
NCT05646719
Eye Diseases, Presbyopia
Phoenix, Arizona, United States
View Trial DetailsPilot Dispensing Study of Two Marketed Daily Disposable Multifocal Contact Lenses
NCT07076160
Eye Diseases, Presbyopia
Jacksonville, Florida, United States
View Trial DetailsVisionApp - Refraction and Presbyopia
NCT07570602
Eye Diseases, Presbyopia
Bloomington, Indiana, United States
View Trial Details